Literature DB >> 10473237

In-vitro comparative activity of UR-9825, itraconazole and fluconazole against clinical isolates of Candida spp.

G Ramos1, M Cuenca-Estrella, A Monzón, J L Rodríguez-Tudela.   

Abstract

UR-9825 is a new broad-spectrum triazole antifungal agent with a good pharmacokinetic profile and excellent bioavailability. It shows high in-vitro activity and efficacy in models of systemic candidosis in rats and rabbits, comparing favourably with fluconazole. The purpose of this study was to evaluate the in-vitro activity of UR-9825 and to compare it with that of fluconazole and itraconazole against 283 clinical isolates of Candida spp. UR-9825 was more potent against Candida spp. than both fluconazole and itraconazole, even against some Candida albicans and Candida krusei isolates with decreased susceptibility to fluconazole (MIC 16 mg/L).

Entities:  

Mesh：

Substances：

Year:  1999        PMID： 10473237     DOI： 10.1093/jac/44.2.283

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN： 0305-7453            Impact factor:   5.790


  14 in total

1.  In vitro activities of 10 antifungal drugs against 508 dermatophyte strains.

Authors:  B Fernández-Torres; A J Carrillo; E Martín; A Del Palacio; M K Moore; A Valverde; M Serrano; J Guarro
Journal:  Antimicrob Agents Chemother       Date:  2001-09       Impact factor: 5.191

Review 2.  Emerging drugs and vaccines for candidemia.

Authors:  Brad Moriyama; Lori A Gordon; Matthew McCarthy; Stacey A Henning; Thomas J Walsh; Scott R Penzak
Journal:  Mycoses       Date:  2014-10-08       Impact factor: 4.377

3.  In vitro activities of four novel triazoles against Scedosporium spp.

Authors:  A J Carrillo; J Guarro
Journal:  Antimicrob Agents Chemother       Date:  2001-07       Impact factor: 5.191

4.  In vitro antiproliferative effects and mechanism of action of the new triazole derivative UR-9825 against the protozoan parasite Trypanosoma (Schizotrypanum) cruzi.

Authors:  J A Urbina; R Lira; G Visbal; J Bartrolí
Journal:  Antimicrob Agents Chemother       Date:  2000-09       Impact factor: 5.191

5.  In vitro antifungal activities of the new triazole UR-9825 against clinically important filamentous fungi.

Authors:  J Capilla; M Ortoneda; F J Pastor; J Guarro
Journal:  Antimicrob Agents Chemother       Date:  2001-09       Impact factor: 5.191

6.  Efficacy of albaconazole against Candida albicans in a vaginitis model.

Authors:  Gloria M González; Efrén Robledo; Elvira Garza-González; Mariana Elizondo; J Gerardo González
Journal:  Antimicrob Agents Chemother       Date:  2009-07-27       Impact factor: 5.191

7.  Efficacy of albaconazole (UR-9825) in treatment of disseminated Scedosporium prolificans infection in rabbits.

Authors:  Javier Capilla; Clara Yustes; Emili Mayayo; Belkys Fernández; Montserrat Ortoneda; F Javier Pastor; Josep Guarro
Journal:  Antimicrob Agents Chemother       Date:  2003-06       Impact factor: 5.191

8.  In vitro and in vivo efficacies of the new triazole albaconazole against Cryptococcus neoformans.

Authors:  J L Miller; W A Schell; E A Wills; D L Toffaletti; M Boyce; D K Benjamin; J Bartroli; J R Perfect
Journal:  Antimicrob Agents Chemother       Date:  2004-02       Impact factor: 5.191

9.  In vitro susceptibilities of Malassezia species to a new triazole, albaconazole (UR-9825), and other antifungal compounds.

Authors:  Margarita Garau; Manolo Pereiro; Amalia del Palacio
Journal:  Antimicrob Agents Chemother       Date:  2003-07       Impact factor: 5.191

Review 10.  Treatment of invasive candidiasis in immunocompromised pediatric patients.

Authors:  Brian T Fisher; Theoklis E Zaoutis
Journal:  Paediatr Drugs       Date:  2008       Impact factor: 3.022
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.